While several major biotech companies are laying off employees by the hundreds, one is dropping billions in acquisitions.
The FDA has granted Priority Review of Celcuity’s New Drug Application (“NDA”) for gedatolisib in patients with HR+/HER2-/ PIK3CA wild-type (“WT”) ABC and assigned a Prescription Drug User Fee Act ...
Appointment supports revenue quality and profitability momentum as the Company activates its transformed operating base - Company announces ...
The neuroscience-focused Seaport and blood coagulation specialist Hemab each exceeded their $200 million targets. Both begin ...
Companies are taking control of their own data to tailor AI for their needs. The challenge lies in balancing ownership with ...
The pharma royalty funding market hit a record $10 billion in 2025. A single AI experiment that improved a cancer drug in ...
Company positions itself as the central research hub for patients, clinicians, and compounding pharmacies tracking the ...
In the small-cap biotech space, the biggest opportunities often come from companies working on breakthrough therapies in ...
So, the natural question for Western Mines Group shareholders is whether they should be concerned by its rate of cash burn.
Not every item that McDonald's dreams up will make it onto the menu, such is the case for this fruity broccoli dish meant to ...
Nearly 20 years ago, Gina Ford left Texas to continue her career in the biosciences. At the time, her career development left ...
Developed by Australian biotech company Snoretox in collaboration with Royal Melbourne Institute of Technology (RMIT) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results